[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2014024201A1 - Régulation et contrôle des glycémies d'un sujet et promotion du métabolisme cellulaire par application d'ondes ultrasonores aériennes basse fréquence (20 khz à 70 khz) et machine pour produire les ondes ultrasonores aériennes pour celles-ci - Google Patents

Régulation et contrôle des glycémies d'un sujet et promotion du métabolisme cellulaire par application d'ondes ultrasonores aériennes basse fréquence (20 khz à 70 khz) et machine pour produire les ondes ultrasonores aériennes pour celles-ci Download PDF

Info

Publication number
WO2014024201A1
WO2014024201A1 PCT/IN2012/000642 IN2012000642W WO2014024201A1 WO 2014024201 A1 WO2014024201 A1 WO 2014024201A1 IN 2012000642 W IN2012000642 W IN 2012000642W WO 2014024201 A1 WO2014024201 A1 WO 2014024201A1
Authority
WO
WIPO (PCT)
Prior art keywords
section
microcontroller
dac
aerostimulator
digital
Prior art date
Application number
PCT/IN2012/000642
Other languages
English (en)
Inventor
T. S. Ramchandran
Original Assignee
Ramchandran T S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramchandran T S filed Critical Ramchandran T S
Publication of WO2014024201A1 publication Critical patent/WO2014024201A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
    • A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
    • A61H23/0218—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement
    • A61H23/0236—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive with alternating magnetic fields producing a translating or oscillating movement using sonic waves, e.g. using loudspeakers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0034—Skin treatment

Definitions

  • the present invention relates generally to the application of low frequency airborne ultrasound waves ( 20 Khz to 70 Khz) with the help of a aerostimulator particularly a non-invasive personal aerostimulator to regulate / manage blood glucose levels / promote cell metabolism of a subject throughout the day.
  • Ultrasound which is routinely used for diagnostic imaging applications worldwide is now being adopted in various fields of drug delivery systems and other therapeutic use. Interactions of acoustic ultrasound with biological tissues play an important role in biomedical applications of ultrasound. Low intensity ultrasound is known to permeate the skin, modulate the cell membrane and alter its properties possibly activating signal transduction pathways. The energy absorbed by the enzymes from the ultrasound effects the overall function of the cell. This could lead to the increased production of protein or reduce the depletion of beta cells associated with insulin.
  • GlybetaC -Digital uses the goodness of airborne ultrasonic energy to enhance the cell permeability and help in the transportation of drugs into them thereby increasing the effectiveness of existing drugs.
  • GlybetaC-Digital Aerostimulator uses the principle of transmitting low frequency airborne ultrasound non invasively on humans to promote cell metabolism. The vibratory motion causes energy propagation which brings about a series of cascading effects on the cell membrane. Low frequency ultrasound is capable of maximum penetration and its energy is absorbed by the tissues, nerves etc. This changes the rate of macromolecular synthesis and causes ultrastructural changes within the cells. Enhanced stimulation of the cells by airborne ultrasound allows the permeability of the cells to increase and helps transport of the drugs into them.
  • the ultrasonic energy On passing through the tissue, the ultrasonic energy is absorbed at a rate proportional to the density of the tissue. Absorption of the ultrasound signal results in energy conversion to heat. While this heating effect is extremely small, some enzymes or chemical mediators mediate the activation of intracellular signaling and additional mechanical stimulation of the cell membranes occur too. Ultrasound serves to reestablish or normalize effective metabolic temperatures in areas or in regions where blood flow has been compromised; this effect, while subtle, may be biologically profound.
  • the differential energy absorption of ultrasound also gives rise to the phenomenon of acoustic streaming, or the movement of fluid.
  • the acoustic streaming and the resultant pressure may mechanistically advance signal-transduction pathways, a process referred to as mechanotransduction.
  • mechanotransduction a process referred to as mechanotransduction.
  • the introduction of an ultrasound signal stimulates a dynamic physical environment.
  • the enhanced movement of the fluid increases the processes of nutrient delivery and waste removal i.e Endocytosis and Exocytosis in the cells. It is likely that the acoustic signal is recognized and is strongly influential in the biology of the cells.
  • Optimal ultrasound has the capability to open, holes in cell membranes like the transport proteins integrated into the cell membranes. These proteins are transported by diffusion or assisted by the concentration gradient across the cell.
  • the drugs are absorbed inside the cells by a process akin to Endocytosis, wherein the ultrasound assisted drug is released or transported inside the cell by opening the cell membrane and releasing the drug inside.
  • the drug delivery is maximized while cell viability is maintained.
  • Cell membranes opened due to the above processes are closed immediately by the internal cellular patching process.
  • Airborne Ultrasound waves Piezoelectric crystals are used for generating ultrasound waves.
  • the crystals are deformed in response to high frequency signals applied to them in the form of electrical voltage and ultrasonic waves are generated .
  • GlySetaC Aerostimulator uses state of the art quartz crystal technology to generate ultrasonic sound waves which gives a micromassage and thermal effect in tissues and produces mechanical stimulation of the receptors in the human body,
  • GiyBetac Aerostimulator has variable modulations with a wide frequency bandwidth to allow a variety of waveforms which ensure that the body tissues do not develop immunity to any specific frequency.
  • GlyBe!aC Aerostimulator uses the principle of transmitting low frequency airborne ultrasound non !fwasiveiy on humans to promote cell metabolism.
  • Giucose is an essential substrate tor the metabolism of most cells.
  • the vibratory motion of ultrasound causes energy propagation which brings about a series of cascading effects on the ceil membrane.
  • Low frequency ultrasound Is capable ol maximum penetration and its energy is absorbed by the tissues, nerves etc. This changes the rate of macromo!ecular synthesis and causes ultrastructural changes within the cells.
  • Transmission of ultrasound waves produces a micromassage effect in tissues and enhances mechanical stimulation of the receptors in human body. Enhanced stimulation of the cells by airborne ultrasound allows the permeability of the cells to improve and helps transport of glucose into them.
  • the ultrasonic energy On passing through the tissue, the ultrasonic energy is absorbed at a rate ' proportional to the density of the tissue. Absorption of the ultrasound signal results in energy conversion to heat. This heating effect is extremely small because of pulsed form of transmission.
  • Ultrasound have Thermal and non thermal effects on the tissues. Energy attenuated by tissues ieads to thermal increase and this thermal energy allows Facilitated diffusion of giucose thereby helping the transport of glucose into cells.
  • Non thermal effects of Ultrasound are Stable Cavitation and Acoustic streaming. These mechanisms cause movements and transfers of intracellular and extracellular ions.
  • FIG. 1 A shows the block diagram of the digital aero stimulator
  • FIG. IB shows the different essential parts of the digital aero stimulator
  • FIG. 2 shows the Input bridge section of the digital aero stimulator
  • FIG. 3 shows the circuit diagram of microcontroller power section
  • FIG. 4 shows the details of micro controller section
  • FIG. 5. shows the DAC for wave generation
  • FIG. 6 shows the voltage gain opamp section
  • FIG. 7 shows the Regulated AC using LM317
  • FIG. 8 shows the ouput drive section of the digital aero stimulator
  • FIG. 9 shows the MosFET H-Bridge Section
  • FIG.10 to 13 explain the thermal action and the non-thermal action of the ultrasound wave.
  • FIGS. 1 through 9 there is shown the details of the digital aero stimulator.
  • GlyBetaC DIGITAL comprises of the following sections
  • UA78M33 Provides regulated 3.3VDC for microcontroller section.
  • Cap C3, C4 are used as Filter Caps.
  • LED L2 Serves the purpose of Indication.
  • Microcontroller Used is MSP430F5310.
  • PINs TEST, TDO, TDI, TMS, TCK, RST are used as JTAG pins to Program the firmware into microcontroller.
  • Yl - is Crystal Oscillator which gives 16MHz Clock Frequency for Micro.
  • Caps CI & C2 are used as Decoupling Caps for Crystal Oscillator supply.
  • the Microcontroller (section.1-3) updates DAC with values stored in its look-up table to form a full sine wave at its output.
  • the opamp is configured as a non inverting single supply gain stage.
  • the Feedback resistor (R14) and Input resistance (R15) decide the gain of
  • the output of the opamp section.1-5 is fed to the adjust pin of the LM317.
  • Driver IC U5 (UCC27425P) drives Sweep signal from microcontroller.
  • CAPs CI 6, C6 & C7 are used as decoupling Capacitors for UCC27425P.
  • Zener Diodes - Z2 & Z3 are used voltage regulator for UCC27425.
  • H-Bridge Used here is ZXMHC3 AO 1 T8 (3 Amp, 30V) (Zetex Make).
  • CAPs C5, C26 are used as Decoupling capacitors for H-Bridge.
  • Diodes D7 & D5 are used to cut down offset voltage.
  • Output section is powered with 100Hz full wave rectified labeled 20Vpp_AC_100Hz - Section.1 -6 .
  • GlybetaC-Digital Aerostimulator consists of a console with a Quartz crystal transducer fixed to it.
  • GlybetaC-Digital Aerostimulator is made as per the guidelines / safety standards laid down by
  • Gly BetaC Aerostimulator improves and enhances quality of life:
  • Digital aerostimulator is not intended to replace medication but to enhance its effect.
  • the effectiveness can be maintained by increasing or decreasing time of exposure depending upon the type of people. Obese people can use the machine for longer time compared to normal people.
  • digital aerostimulator is not intended to be used as medical advice, or to diagnose, treat, cure, or prevent any disease nor should it be used for therapeutic purposes or a substitute for a Health professional's advice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

La présente invention concerne un aérostimulateur numérique ou un émetteur d'ondes ultrasonores aériennes comprenant une section de pont d'entrée pour alimentation d'onde totale non régulée (Vcc) à un régulateur de tension, un amplificateur opérationnel (op-amp) et un générateur d'onde sinusoïdale. Une section d'alimentation de microcontrôleur comprenant un régulateur de tension UA78M33 et des condensateurs pour la filtration de signal et un LED pour indication de statut, la sortie du pont d'entrée Vcc étant transmise en tant qu'entrée au UA78M33. Il comprend en outre une section de microcontrôleur centrée autour d'un microcontrôleur MSP430F2121IDW et un DAC (convertisseur numérique-analogique) pour génération d'onde sinusoïdale totale qui est fonctionnellement couplé au microcontrôleur. La section de microcontrôleur met à jour le DAC avec des valeurs stockées dans sa table de référence pour former une onde sinusoïdale complète à sa sortie. De plus, le dispositif comprend un étage d'amplification de tension OP-AMP et un étage d'amplification de courant CA régulé, une section d'excitation de sortie, une section de pont en H MosFET et un transducteur à ultrasons.
PCT/IN2012/000642 2012-08-06 2012-09-26 Régulation et contrôle des glycémies d'un sujet et promotion du métabolisme cellulaire par application d'ondes ultrasonores aériennes basse fréquence (20 khz à 70 khz) et machine pour produire les ondes ultrasonores aériennes pour celles-ci WO2014024201A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2251/MUM/2012 2012-08-06
IN2251MU2012 2012-08-06

Publications (1)

Publication Number Publication Date
WO2014024201A1 true WO2014024201A1 (fr) 2014-02-13

Family

ID=47844416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000642 WO2014024201A1 (fr) 2012-08-06 2012-09-26 Régulation et contrôle des glycémies d'un sujet et promotion du métabolisme cellulaire par application d'ondes ultrasonores aériennes basse fréquence (20 khz à 70 khz) et machine pour produire les ondes ultrasonores aériennes pour celles-ci

Country Status (1)

Country Link
WO (1) WO2014024201A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
WO2020186073A1 (fr) * 2019-03-12 2020-09-17 General Electric Company Neuromodulation pour cibler les voies des transporteurs de glucose et/ou des incrétines
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460595A (en) * 1993-06-01 1995-10-24 Dynatronics Laser Corporation Multi-frequency ultrasound therapy systems and methods
US20040013420A1 (en) * 2002-07-17 2004-01-22 Minolta Co., Ltd. Driving device, position controller provided with driving device, and camera provided with position controller
US20080281238A1 (en) * 2007-05-09 2008-11-13 Tsutomu Oohashi Oscillation representing system for effectively applying hypersonic sound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460595A (en) * 1993-06-01 1995-10-24 Dynatronics Laser Corporation Multi-frequency ultrasound therapy systems and methods
US20040013420A1 (en) * 2002-07-17 2004-01-22 Minolta Co., Ltd. Driving device, position controller provided with driving device, and camera provided with position controller
US20080281238A1 (en) * 2007-05-09 2008-11-13 Tsutomu Oohashi Oscillation representing system for effectively applying hypersonic sound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"GlyBetaC Brochure", 2 March 2011 (2011-03-02), Website of MASER ELECTRONICS (P) LTD, XP055063086, Retrieved from the Internet <URL:http://web.archive.org/web/20110302105935/http://www.maserindia.com/pdf/GlyBetaC_Brochure.pdf> [retrieved on 20130515] *
"GlyBetaC product page", 18 July 2010 (2010-07-18), Website of MASER ELECTRONICS (P) LTD, XP055063090, Retrieved from the Internet <URL:http://web.archive.org/web/20100718170828/http://www.maserindia.com/Glybetac.html> [retrieved on 20130515] *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10629294B2 (en) 2012-09-11 2020-04-21 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9483619B2 (en) 2012-09-11 2016-11-01 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US11733196B2 (en) 2012-09-11 2023-08-22 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US11131643B2 (en) 2012-09-11 2021-09-28 Aseko, Inc. Method and system for optimizing insulin dosages for diabetic subjects
US10410740B2 (en) 2012-09-11 2019-09-10 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9773096B2 (en) 2012-09-11 2017-09-26 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9811638B2 (en) 2012-09-11 2017-11-07 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US10102922B2 (en) 2012-09-11 2018-10-16 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9965596B2 (en) 2012-09-11 2018-05-08 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9710611B2 (en) 2014-01-31 2017-07-18 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US12127831B2 (en) 2014-01-31 2024-10-29 Aseko, Inc. Insulin management
US9965595B2 (en) 2014-01-31 2018-05-08 Aseko, Inc. Insulin management
US12027266B2 (en) 2014-01-31 2024-07-02 Aseko, Inc. Insulin management
US11857314B2 (en) 2014-01-31 2024-01-02 Aseko, Inc. Insulin management
US10255992B2 (en) 2014-01-31 2019-04-09 Aseko, Inc. Insulin management
US11804300B2 (en) 2014-01-31 2023-10-31 Aseko, Inc. Insulin management
US11783945B2 (en) 2014-01-31 2023-10-10 Aseko, Inc. Method and system for insulin infusion rate management
US9604002B2 (en) 2014-01-31 2017-03-28 Aseko, Inc. Insulin management
US10453568B2 (en) 2014-01-31 2019-10-22 Aseko, Inc. Method for managing administration of insulin
US10535426B2 (en) 2014-01-31 2020-01-14 Aseko, Inc. Insulin management
US11783946B2 (en) 2014-01-31 2023-10-10 Aseko, Inc. Method and system for insulin bolus management
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9892235B2 (en) 2014-01-31 2018-02-13 Aseko, Inc. Insulin management
US10811133B2 (en) 2014-01-31 2020-10-20 Aseko, Inc. System for administering insulin boluses to a patient
US11081233B2 (en) 2014-01-31 2021-08-03 Aseko, Inc. Insulin management
US9504789B2 (en) 2014-01-31 2016-11-29 Aseko, Inc. Insulin management
US11621074B2 (en) 2014-01-31 2023-04-04 Aseko, Inc. Insulin management
US11158424B2 (en) 2014-01-31 2021-10-26 Aseko, Inc. Insulin management
US11311213B2 (en) 2014-01-31 2022-04-26 Aseko, Inc. Insulin management
US11468987B2 (en) 2014-01-31 2022-10-11 Aseko, Inc. Insulin management
US11490837B2 (en) 2014-01-31 2022-11-08 Aseko, Inc. Insulin management
US10128002B2 (en) 2014-10-27 2018-11-13 Aseko, Inc. Subcutaneous outpatient management
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
US11678800B2 (en) 2014-10-27 2023-06-20 Aseko, Inc. Subcutaneous outpatient management
US11694785B2 (en) 2014-10-27 2023-07-04 Aseko, Inc. Method and dosing controller for subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US10403397B2 (en) 2014-10-27 2019-09-03 Aseko, Inc. Subcutaneous outpatient management
US12023127B2 (en) 2014-10-27 2024-07-02 Aseko, Inc. Subcutaneous outpatient management
US9886556B2 (en) 2015-08-20 2018-02-06 Aseko, Inc. Diabetes management therapy advisor
US10380328B2 (en) 2015-08-20 2019-08-13 Aseko, Inc. Diabetes management therapy advisor
US11574742B2 (en) 2015-08-20 2023-02-07 Aseko, Inc. Diabetes management therapy advisor
US12040096B2 (en) 2015-08-20 2024-07-16 Aseko, Inc. Diabetes management therapy advisor
WO2020186073A1 (fr) * 2019-03-12 2020-09-17 General Electric Company Neuromodulation pour cibler les voies des transporteurs de glucose et/ou des incrétines
US12029577B2 (en) 2019-03-12 2024-07-09 GE Precision Healthcare LLC Neuromodulation to target glucose transporter and/or incretin pathways
CN113557058A (zh) * 2019-03-12 2021-10-26 通用电气公司 靶向葡萄糖转运子和/或肠促胰岛素途径的神经调节

Similar Documents

Publication Publication Date Title
WO2014024201A1 (fr) Régulation et contrôle des glycémies d&#39;un sujet et promotion du métabolisme cellulaire par application d&#39;ondes ultrasonores aériennes basse fréquence (20 khz à 70 khz) et machine pour produire les ondes ultrasonores aériennes pour celles-ci
US9433803B2 (en) Method and system for destroying adipose tissue non-invasively and accelerating lipid metabolism
US8469906B2 (en) Therapeutic micro-vibration device
TWI505825B (zh) 治療微振動裝置
Ngo et al. Development of low frequency (20–100 kHz) clinically viable ultrasound applicator for chronic wound treatment
KR20100079448A (ko) 밴드부직형 초음파 압전센서를 이용한 초음파 생성장치
KR200377073Y1 (ko) 피부 연조직 활성화용 레이저 치료기에 진동자가 구비된초음파 치료기가 복합된 치료기
CN204050696U (zh) 一种可添加液体药物的超声波治疗仪
CN204050691U (zh) 一种带监控功能的超声波治疗仪
KR102085220B1 (ko) 매개체를 이용한 비침습적 치료시스템
KR20080048817A (ko) 복합 진동 발생장치
KR20030014548A (ko) 한약물을 이용한 초음파 물리치료기
CN102406982A (zh) 超声波治疗静脉曲张的方法及装置
CN102327673A (zh) 超声波治疗便秘的方法及装置
CN102397152A (zh) 超声波治疗颈椎病的方法及装置
KR20130122857A (ko) 열과 파동의 심부 전달 기능을 갖는 부항장치
CN102406983A (zh) 超声波治疗脑炎的方法及装置
Tiwari et al. Design and implementation of complete wearable low-intensity pulsed ultrasound therapeutic device
Vigneshwari et al. Low-Frequency Ultrasound Therapeutic Device For Soft Tissue Healing
CN102397639A (zh) 超声波治疗耳鸣的方法及装置
CN102397644A (zh) 超声波结合肠胃下垂药物治疗肠胃下垂的方法及装置
CN102397151A (zh) 超声波治疗腰椎病的方法及装置
CN108355259A (zh) 一种超声波结合肠胃下垂药物治疗肠胃下垂的方法及装置
KR20130122860A (ko) 열과 파동의 심부 전달 기능을 갖는 부항 사용 방법
CN102397649A (zh) 超声波结合万艾可或激活性药物治疗糖尿病的方法及装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12830889

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12830889

Country of ref document: EP

Kind code of ref document: A1